Rafferty Asset Management
JAZZ icon

Rafferty Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rafferty Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Buy
1,853
+205
+12% +$44.9K ﹤0.01% 920
2026
Q1 		$312K Sell
1,648
-791
-32% -$138K ﹤0.01% 951
2025
Q4 		$415K Sell
2,439
-313
-11% -$48K ﹤0.01% 940
2025
Q3 		$363K Sell
2,752
-474
-15% -$56.9K ﹤0.01% 951
2025
Q2 		$342K Sell
3,226
-239
-7% -$26K ﹤0.01% 957
2025
Q1 		$430K Sell
3,465
-855
-20% -$112K ﹤0.01% 901
2024
Q4 		$532K Sell
4,320
-1,137
-21% -$134K ﹤0.01% 896
2024
Q3 		$608K Buy
5,457
+326
+6% +$35.7K ﹤0.01% 892
2024
Q2 		$548K Buy
5,131
+815
+19% +$89.6K ﹤0.01% 928
2024
Q1 		$520K Buy
4,316
+914
+27% +$112K ﹤0.01% 966
2023
Q4 		$418K Buy
3,402
+705
+26% +$88K ﹤0.01% 1007
2023
Q3 		$349K Buy
2,697
+170
+7% +$22.7K ﹤0.01% 998
2023
Q2 		$313K Buy
2,527
+561
+29% +$75.5K ﹤0.01% 1035
2023
Q1 		$288K Sell
1,966
-222
-10% -$32.8K ﹤0.01% 1047
2022
Q4 		$349K Buy
2,188
+276
+14% +$40.5K ﹤0.01% 973
2022
Q3 		$255K Buy
1,912
+27
+1% +$4.11K ﹤0.01% 1042
2022
Q2 		$294K Sell
1,885
-1,257
-40% -$194K ﹤0.01% 921
2022
Q1 		$489K Sell
3,142
-4,380
-58% -$636K ﹤0.01% 1005
2021
Q4 		$958K Buy
7,522
+1,829
+32% +$240K 0.01% 882
2021
Q3 		$741K Sell
5,693
-129
-2% -$19.5K 0.01% 952
2021
Q2 		$1.03M Buy
5,822
+297
+5% +$51.4K 0.01% 879
2021
Q1 		$908K Sell
5,525
-233
-4% -$38.3K 0.01% 792
2020
Q4 		$950K Buy
5,758
+410
+8% +$61.1K 0.01% 515
2020
Q3 		$763K Buy
5,348
+2,441
+84% +$303K 0.01% 618
2020
Q2 		$321K Buy
+2,907
New +$321K ﹤0.01% 812
2020
Q1 		– Sell
-11,630
Closed -$1.74M – 704
2019
Q4 		$1.74M Buy
11,630
+7,682
+195% +$1.05M 0.03% 432
2019
Q3 		$506K Buy
3,948
+1,847
+88% +$248K 0.01% 660
2019
Q2 		$300K Buy
+2,101
New +$282K 0.01% 747

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Rafferty Asset Management's JAZZ Position: Q2 2026 in Review

Rafferty Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 12% in Q2 2026, buying an estimated $44.9K and bringing the position to 1,853 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #920.

Rafferty Asset Management first reported a position in JAZZ in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.74M in Q4 2019. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Rafferty Asset Management held 1,853 shares of Jazz Pharmaceuticals worth $447K as of Q2 2026.
  • Rafferty Asset Management bought 205 Jazz Pharmaceuticals shares in Q2 2026, an estimated $44.9K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #920 holding.
  • Rafferty Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Rafferty Asset Management's Jazz Pharmaceuticals position peaked at $1.74M in Q4 2019.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.